<DOC>
	<DOCNO>NCT02175680</DOCNO>
	<brief_summary>This study Phase 2b study design evaluate efficacy , safety , tolerability PRO 140 monotherapy maintenance viral suppression subject stable combination antiretroviral therapy . Consenting subject shift combination antiretroviral regimen PRO 140 monotherapy 12 week . Total treatment duration PRO 140 14 week one week overlap exist retroviral regimen PRO 140 begin study treatment , one week overlap end treatment subject experience virologic failure .</brief_summary>
	<brief_title>Treatment Substitution With PRO 140 Monotherapy Adult Subjects With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>1 . Males female , age ≥18 year 2 . Exclusive CCR5tropic virus Screening Visit determine Trofile™ DNA Assay 3 . On stable antiretroviral therapy last 12 month 4 . Subject two potential alternative antiretroviral regimen option consider . 5 . No documented detectable viral load ( HIV1 RNA &lt; 50 copies/ml ) within last 12 month prior Screening Visit 6 . Nadir CD4 cell count &gt; 200 cells/mm3 1 . CXCR4tropic virus dual/mixed tropic ( R5X4 ) virus determine Trofile™ DNA Assay Screening Visit 2 . Hepatitis B infection manifest presence Hepatitis B surface antigen ( HBsAg ) 3 . Any acquire immune deficiency syndrome ( AIDS ) define illness accord 1993 Centers Disease Control Prevention ( CDC ) AIDS surveillance definition 4 . Prior use entry , attachment , CCR5 coreceptor , fusion inhibitor , include PRO 140 . 5 . Any clinical condition , Investigator 's judgment , would potentially compromise study compliance ability evaluate safety/efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Substitution</keyword>
	<keyword>PRO 140</keyword>
	<keyword>PRO140</keyword>
	<keyword>CytoDyn</keyword>
	<keyword>Amarex</keyword>
</DOC>